Caption Management LLC Increases Stock Holdings in Avadel Pharmaceuticals PLC. $AVDL

Key Points

• Caption Management LLC increased its holdings in Avadel Pharmaceuticals PLC by 65.6%, acquiring an additional 104,910 shares, bringing its total to 264,910 shares valued at $2.07 million.
• Avadel Pharmaceuticals recently reported a quarterly EPS of $0.10, exceeding expectations, and experiencing a 64.1% year-over-year revenue increase of $68.13 million.
• Analysts maintain a positive outlook for Avadel Pharmaceuticals, with seven firms giving it a "Buy" or "Strong buy" rating and an average price target of $19.67.

Caption Management LLC lifted its position in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) by 65.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,910 shares of the company's stock after purchasing an additional 104,910 shares during the period. Caption Management LLC owned about 0.27% of Avadel Pharmaceuticals worth $2,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in AVDL. Invesco Ltd. lifted its stake in shares of Avadel Pharmaceuticals by 2.3% in the 4th quarter. Invesco Ltd. now owns 52,142 shares of the company's stock valued at $548,000 after purchasing an additional 1,177 shares during the period. First Trust Advisors LP lifted its stake in shares of Avadel Pharmaceuticals by 779.4% in the 4th quarter. First Trust Advisors LP now owns 106,729 shares of the company's stock valued at $1,122,000 after purchasing an additional 94,592 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Avadel Pharmaceuticals by 6.1% in the 4th quarter. MetLife Investment Management LLC now owns 57,068 shares of the company's stock valued at $600,000 after purchasing an additional 3,271 shares during the period. Hsbc Holdings PLC acquired a new position in Avadel Pharmaceuticals during the fourth quarter worth $113,000. Finally, Price T Rowe Associates Inc. MD raised its position in Avadel Pharmaceuticals by 21.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 36,673 shares of the company's stock worth $386,000 after acquiring an additional 6,445 shares during the period. 69.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $24.00 price objective (up from $22.00) on shares of Avadel Pharmaceuticals in a research report on Friday, August 8th. Wells Fargo & Company assumed coverage on shares of Avadel Pharmaceuticals in a research report on Tuesday. They set an "equal weight" rating and a $16.00 price objective for the company. Wall Street Zen upgraded shares of Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, Zacks Research upgraded shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $19.14.

Avadel Pharmaceuticals Stock Performance

Shares of NASDAQ AVDL traded down $0.32 during mid-day trading on Wednesday, reaching $14.66. The company's stock had a trading volume of 2,288,973 shares, compared to its average volume of 1,338,178. The stock has a 50-day moving average of $11.75 and a two-hundred day moving average of $9.65. The stock has a market capitalization of $1.42 billion, a P/E ratio of -488.67 and a beta of 1.58. Avadel Pharmaceuticals PLC. has a 1-year low of $6.38 and a 1-year high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million during the quarter, compared to analysts' expectations of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The company's quarterly revenue was up 64.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Avadel Pharmaceuticals PLC. will post -0.51 EPS for the current fiscal year.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.